Crinetics Pharmaceuticals
CRNX
CRNX was delisted on the 31st of August, 2026.
222 hedge funds and large institutions have $3.01B invested in Crinetics Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 35 funds opening new positions, 94 increasing their positions, 66 reducing their positions, and 37 closing their positions.
634% more call options, than puts
Call options by funds: $3.14M | Put options by funds: $428K
42% more repeat investments, than reductions
Existing positions increased: 94 | Existing positions reduced: 66
2.16% more ownership
Funds ownership: 109.51% → 111.67% (+2.2%)
5% less first-time investments, than exits
New positions opened: 35 | Existing positions closed: 37
2% less funds holding
Funds holding: 227 → 222 (-5)
12% less capital invested
Capital invested by funds: $3.42B → $3.01B (-$412M)
33% less funds holding in top 10
Funds holding in top 10: 9 → 6 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$37.7M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$19M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$14.8M |
| 4 |
RI
RTW Investments
New York
|
+$14.4M |
| 5 |
Goldman Sachs
New York
|
+$12.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$33.5M |
| 2 |
SG Americas Securities
New York
|
-$15.5M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
-$11.7M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$9.7M |
| 5 |
VOYA Investment Management
Atlanta,
Georgia
|
-$9.56M |
CRNX Hedge Fund Activity: Q2 2025 in Review
222 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in Crinetics Pharmaceuticals (CRNX) for Q2 2025, worth a combined $3.01B — down 12% from $3.42B a quarter earlier.
Sellers outnumbered buyers: 37 funds closed out of CRNX and 35 opened new positions — a net loss of 2 holders — while 66 trimmed existing stakes and 94 added.
The largest buyer was Point72 Asset Management, adding an estimated $37.7M. The largest seller was Wellington Management Group, cutting an estimated $33.5M.
- 222 institutional investors held Crinetics Pharmaceuticals (CRNX) as of Q2 2025, down from 227 in Q1 2025.
- Funds reported $3.01B of Crinetics Pharmaceuticals stock for Q2 2025, down 12% quarter-over-quarter.
- 35 funds opened new Crinetics Pharmaceuticals positions in Q2 2025 and 37 closed out, a net change of -2 holders.
- The largest Crinetics Pharmaceuticals buyer in Q2 2025 was Point72 Asset Management, an estimated $37.7M added.
- The largest Crinetics Pharmaceuticals seller in Q2 2025 was Wellington Management Group, an estimated $33.5M sold.
Based on aggregated 13F filings for Q2 2025.